Philogen Announces R&D Program Update | Comunicados | Edición USA efe.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from efe.com Daily Mail and Mail on Sunday newspapers.
Philogen Announces First Quarter 2021 Results and Provides Update on Pipeline Progress
May 12, 2021 on track for
Phase III European trial in stage IIIB/C melanoma. Opening of additional clinical centers to boost recruitment rate is ongoing. E
Fibromun
Philogen is well capitalized, about
th the
here (https://us06web.zoom.us/webinar/register/WN nEuoFxsHTXSTdtS4RBslYg)
Siena (Italy), 12 May 2021 - (Globe Newswire) - Philogen S.p.A. (BIT:PHIL) - a listed clinical-stage biotechnology company focused on the development of innovative medicines based on tumor targeting antibodies and small molecule ligands, is pleased to announce progress updates for its fully-owned immunocytokine and small molecule programs.
Press release content from Newswire. The AP news staff was not involved in its creation.
Philogen Announces Publication of the Construction and Application of an Innovative DNA-Encoded Chemical Library in Nature Chemistry
April 12, 2021 GMT
Philogen Announces Publication of the Construction and Application of an Innovative DNA-Encoded Chemical Library in Nature Chemistry
Philogen Announces Publication of the Construction and Application of an Innovative DNA-Encoded Chemical Library in Nature Chemistry
SIENA, Italy - April 12, 2021 - ( Newswire.com )
Philogen S.p.A., a listed clinical-stage biotechnology company focused on the development of innovative medicines based on tumor-targeting antibodies and small molecule ligands, is pleased to announce a publication describing the construction of a DNA-encoded chemical library (DEL) that was successfully screened against multiple protein targets, yielding potent and selective small molecule binders against disease-relevant antigens.
Press release content from Newswire. The AP news staff was not involved in its creation.
Philogen Announces Participation to the 10th World Congress of Melanoma
April 12, 2021 GMT
Philogen Announces Participation to the 10th World Congress of Melanoma
SIENA, Italy - April 12, 2021 - ( Newswire.com )
Philogen S.p.A., a listed clinical-stage biotechnology company focused on the development of innovative medicines based on tumor-targeting antibodies and small molecule ligands, is pleased to announce its participation in the 10th World Congress of Melanoma, a virtual event taking place from April 15 to 17, 2021.
Philogen, which is one of the sponsors of this congress, will give a poster presentation with the title: “A phase II study of intralesional Daromun (L19IL2 + L19TNF) in non-melanoma skin cancer patients with localized disease (NCT04362722)”. The poster will be on display for registered participants starting from Monday, April 12, 2021.